Mfg e8

Pancreatic AR42J cells (zq0145, ScienCell Research Laboratories, Inc., Shanghai, China) were cultured in Ham's F‐12K medium (Procell Life Science&Technology Co., Ltd., Wuhan, China) with 20% fetal bovine serum in a humidified incubator at 37°C with 5% CO₂⁵⁸. AR42J cells (5 × 10⁵/well) were plated into six‐well culture plates for 24 h. Then, the cells were treated with 100 nmol/L cerulein (C6660, Solarbio, USA) and 10 ng/mL lipopolysaccharide (LPS; L‐8880, Solarbio, USA) with or without 20 or 100 ng/mL MFG‐E8 (2805‐MF, RD System, Inc. Minnesota, USA) for 24 h. In additional groups of AR42J cells, PF00562271 (S2672, SELLECK, Texas, USA), a specific FAK inhibitor or APTSTAT3‐9R (S8197, SELLECK, Texas, USA), a specific STAT3 antagonist, were administered together with 100 ng/mL MFG‐E8.

The AR42J cells were treated with 100 nmol/L cerulein (C6660, Solarbio, United States) and 10 ng/ml Lipopolysaccharide (LPS) (L-8880, Solarbio, United States) with or without 20 or 100 ng/ml MFG-E8 (2805-MF, RD System, Inc. Minnesota, United States) for 24 h. In additional groups of AR42J cells, Cilengitide (5 ng/ml, SELLECK, Texas, United States), a specific αvβ3/5 integrin inhibitor or PF00562271 (S2672, SELLECK, Texas, United States), a specific FAK inhibitor or APTSTAT3-9R (S8197, SELLECK, Texas, United States), a specific STAT3 antagonist, were administered together with 100 ng/ml MFG-E8.